Aspen and the Russian Far Eastern Federal University enter into collaborative venture

Johannesburg, 11 July 2017 – Aspen Pharmacare, South Africa’s largest pharmaceutical company and in the JSE’s top twenty, has partnered with Russia’s Federal State Autonomous Educational Institution of Higher Education, the Far Eastern Federal University (FEFU), to promote the study and use of sophisticated and innovative technologies in the fields of thrombosis and anaesthesiology.

Stavros Nicolaou, Senior Executive, Strategic Trade Development at Aspen, who was present at the signing of the accord with Russian Deputy Prime Minister, Mr. Yuri Trutnev, who is also presidential envoy to Russia’s Far Eastern Province, hailed the agreement as a significant step towards the reduction of thrombotic incidents in the Russian Federation.

“The collaboration aims mainly at reducing the number of deaths associated with thrombosis which is relatively high in Russia compared to rates in the European Union,” he comments.

“In fact, the current usage per capita of anti-coagulants, which treat thrombosis, is only around 10% of that used in the EU. This will focus on improving both awareness and broader education on improving treatment of thrombosis and the use of anaesthetics and how these can be used to improve the overall life expectancy of patients. We will also be undertaking joint training and research programmes to further develop the already advanced technologies.”

Anti-thrombotic medication reduces the formation of blood clots in veins and arteries, which can lead to coronary or pulmonary thrombosis, heart attack and death.

Aspen has been established in the Russian Federation since 2013, where it is a leader in the State-funded and medically critical fields of anti-thrombosis and anaesthesiology. Now operating throughout Russia, as well as the Far Eastern Federal District, Aspen employs over 150 qualified specialists in that country.

One of the main pharmaceuticals in Aspen’s Russian portfolio is the life-saving injectable anti-coagulant, Fraxiparine (Nadroparine Calcium). This low molecular-weighted heparin encompasses unique manufacturing technology and boasts a best-in-class efficacy and safety profile.

The first phase of Aspen’s technology transfer for full-cycle manufacturing of Fraxiparine has been completed at the Russian bio-pharmaceutical company Nanolek LLC, in the Kirov Region.

“This collaboration is significant from a South African perspective, as it underscores the confidence that countries around the world have in Aspen’s scientific capabilities and begins to profile South Africa as a global pharmaceutical player. Up until now South Africa was viewed very much as a local pharmaceutical player,” added Nicolaou.

Nicolaou, says that Fraxiparine has already been launched in South Africa where it is expected to contribute significantly to the reduction of thrombosis-associated mortality in our country.

“The incidence of thrombosis in South Africa is on the increase and the inclusion of Fraxiparine in the Aspen Thrombosis basket is an important development in this field.”

Aspen, which is Africa’s largest and the world’s ninth-largest generic pharmaceutical company in revenues, with a market capitalisation of about $10 billion (R128.52 bn), boasts a proud track record of over 160 years and has a strong global presence in both emerging and developed countries, where it operates more than 60 established business operations in some 50 countries. 

Issued by          Nkini Phasha, Bakone Strategic Concepts Group.

                           Tel: 011 022 5700; e-mail:

On behalf of      Stavros Nicolaou, Aspen Pharmacare.

Tel: 011 239 6798; e-mail:

For further information or assistance, please contact:

Aspen’s medical information hotline: 0800 118 088